On Oct 28, major Wall Street analysts update their ratings for $Colgate-Palmolive (CL.US)$, with price targets ranging from $92 to $112.
Morgan Stanley analyst Dara Mohsenian maintains with a buy rating, and maintains the target price at $111.
Barclays analyst Lauren Lieberman maintains with a hold rating, and adjusts the target price from $84 to $96.
Wells Fargo analyst Christopher Carey maintains with a sell rating, and maintains the target price at $92.
Evercore analyst Robert Ottenstein maintains with a buy rating, and maintains the target price at $112.
TD Cowen analyst Robert Moskow maintains with a buy rating, and adjusts the target price from $115 to $110.
Furthermore, according to the comprehensive report, the opinions of $Colgate-Palmolive (CL.US)$'s main analysts recently are as follows:
Colgate-Palmolive's shares experienced a sell-off even though third-quarter estimates were surpassed, which is attributed more to profit-taking than underlying fundamental issues. Despite North American sales not meeting expectations, which was probably a key factor in the stock's underperformance, the anticipated positive turn in the North America division in the fourth quarter is likely due to a mix of shipment timing, innovative efforts, and overcoming previous allocation challenges.
The recent decline in Colgate-Palmolive's stock, despite surpassing third-quarter expectations and raising future projections, is believed to be due to market worries over peak valuations and doubts regarding the enduring nature of their current performance. The adjustment of the target reflects a broader trend of lower multiples throughout the sector. Nevertheless, this is seen as a favorable opportunity for investors seeking stable consumer packaged goods companies with a view through 2025.
Colgate-Palmolive's third quarter showed solid performance, yet the company's stock has witnessed a decline. The expectation is for market trends to continue normalizing, which contrasts with a valuation that remains somewhat elevated, particularly when considering a slight adjustment to earnings per share projections for 2025.
Colgate-Palmolive's fundamentals remain robust, demonstrated by a 4% increase in volume in the third quarter, following a 3% rise in the first half of 2024, positioning it as one of the top performers among large-cap consumer staples entities. Despite this, there is an expectation for a deceleration in Colgate's organic sales growth, transitioning from the high single-digits of recent years to a forecasted 4%-5% over the upcoming four quarters. This projected slowdown suggests that the stock's current valuation may not experience an upward re-rating.
Here are the latest investment ratings and price targets for $Colgate-Palmolive (CL.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
